Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 10:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 2,427 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 0.9 % sodium chloride Clear all
Completed Phase 2 Interventional Results available

Safety Evaluation of 3K3A-APC in Ischemic Stroke

NCT02222714
View directory record Official record
Conditions
Ischemic Stroke
Interventions
3K3A-APC, Placebo
Biological · Drug
Lead sponsor
ZZ Biotech, LLC
Industry
Eligibility
18 Years to 90 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
15
States / cities
Los Angeles, California • Chicago, Illinois • Kansas City, Kansas + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2018 · Synced Oct 18, 2026, 10:16 AM EDT
Completed Phase 1 Interventional Results available

Investigation of the Safety of Intranasal Glulisine in Down Syndrome

NCT02432716
View directory record Official record
Conditions
Down Syndrome
Interventions
Insulin glulisine, Saline
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
35 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 6, 2019 · Synced Oct 18, 2026, 10:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Consciousness, Psilocybin, and Well-Being

NCT05592379
View directory record Official record
Conditions
Healthy, Psychedelic Experiences, Sleep
Interventions
Psilocybin, Clonidine, Saline
Drug · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 45 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 18, 2026, 10:16 AM EDT
Terminated Phase 4 Interventional Results available

Efficacy Of Combined Nebulized Hypertonic Saline and Chest Percussion Therapy in Acute Viral Bronchiolitis

NCT06441162
View directory record Official record
Conditions
Acute Bronchiolitis
Interventions
Nebulized 3% sodium chloride solution, Chest percussion cups
Drug · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
0 Months to 24 Months
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 18, 2026, 10:16 AM EDT
Completed Phase 3 Interventional Results available

Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older

NCT00132808
View directory record Official record
Conditions
Osteopenia
Interventions
Zoledronic Acid, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years and older · Female only
Enrollment
581 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 12, 2016 · Synced Oct 18, 2026, 10:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Serum Concentrations of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered in Multiple Doses and Routes to Healthy, HIV-uninfected Adults

NCT03387150
View directory record Official record
Conditions
HIV Infections
Interventions
VRC07-523LS, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
6
States / cities
Birmingham, Alabama • Atlanta, Georgia • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Oct 18, 2026, 10:16 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Restylane Silk for Treatment of Chest Wrinkles

NCT03324997
View directory record Official record
Conditions
Wrinkle
Interventions
Restylane Silk, Saline, Optical Coherence Tomography
Drug · Device
Lead sponsor
Heidi Waldorf
Other
Eligibility
25 Years to 55 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Oct 18, 2026, 10:16 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Botulinum Toxin A (Botox) in Tissue Expander Breast Reconstruction

NCT01591746
View directory record Official record
Conditions
Breast Cancer, Pain, Postoperative, BRCA1 Mutation, BRCA2 Mutation, Breast Diseases, Neoplasms
Interventions
Botulinum Toxin Type A, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Oct 18, 2026, 10:16 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Tariquidar-ondansetron Combination in Neuropathic Pain

NCT04603066
View directory record Official record
Conditions
Neuropathic Pain
Interventions
Ondansetron 16 mg with Tariquidar, Ondansetron 16 mg with Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 18, 2026, 10:16 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat

NCT07140939
View directory record Official record
Conditions
Subcutaneous Fat
Interventions
CBL-514 Injection, 0.9% Sodium Chloride
Drug · Other
Lead sponsor
Caliway Biopharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
11
States / cities
Encinitas, California • West Palm Beach, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 18, 2026, 10:16 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Multimodal Periarticular Injections in Operatively Treated Ankle Fractures

NCT02967172
View directory record Official record
Conditions
Pain, Postoperative, Ankle Fractures
Interventions
Ropivacaine, Epinephrine, Morphine, 0.9% sodium chloride solution
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Oct 18, 2026, 10:16 AM EDT
Terminated Phase 4 Interventional Results available

Trial Comparing Three Single Dose Injections for Knee Osteoarthritis

NCT05492851
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Zilretta, Synvisc-One 48 MG in 6 ML Prefilled Syringe, Monovisc 88 MG Per 4 ML Prefilled Syringe
Drug
Lead sponsor
Ohio State University
Other
Eligibility
25 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Columbus, Ohio • Lewis Center, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 18, 2026, 10:16 AM EDT
Terminated Phase 2 Interventional Results available

Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE)

NCT00599131
View directory record Official record
Conditions
Cancer of Larynx
Interventions
Cisplatin, Cetuximab, 5-Fluorouracil, Docetaxel
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Oct 18, 2026, 10:16 AM EDT
Completed Not applicable Interventional

The Effect of Tranexamic Acid on Blood Coagulation in Total Hip Arthroplasty Surgery

NCT03897621
View directory record Official record
Conditions
Coagulation; Intravascular, Rotational Thromboelastometry, Fibrinolysis; Hemorrhage, Tranexamic Acid, Total Hip Arthroplasty
Interventions
Tranexamic Acid, Placebo
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Oct 18, 2026, 10:16 AM EDT
Terminated Phase 2 Interventional

Phase 2B Micronized DHACM vs. Saline in the Treatment of Knee Osteoarthritis

NCT05796765
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Micronized DHACM 40 mg, Micronized DHACM 100 mg, Saline
Biological · Drug
Lead sponsor
MiMedx Group, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
14
States / cities
La Mesa, California • Miami, Florida • The Villages, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Oct 18, 2026, 10:16 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002

NCT02334436
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum toxin, Type A, 0.9% sterile, unpreserved saline
Biological · Other
Lead sponsor
Evolus, Inc.
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Oct 18, 2026, 10:16 AM EDT
Completed Not applicable Interventional Results available

Addition of Pudendal Blocks to Pelvic Floor Physical Therapy for the Treatment of Pelvic Floor Tension Myalgia

NCT00928564
View directory record Official record
Conditions
Pelvic Floor Muscle Spasm
Interventions
Pudendal block, Placebo
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Oct 18, 2026, 10:16 AM EDT
Completed Not applicable Interventional Results available

NeutraSal Treatment for Xerostomia in OSAS Patients Using CPAP Therapy

NCT02107300
View directory record Official record
Conditions
Xerostomia
Interventions
NeutraSal, Placebo Comparator
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 84 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Oct 18, 2026, 10:16 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Effects of Niacin on Intramyocellular Fatty Acid Trafficking in Upper Body Obesity and Type 2 Diabetes Mellitus

NCT03867500
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Obesity
Interventions
Niacin, Saline
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 17, 2025 · Synced Oct 18, 2026, 10:16 AM EDT
Completed Phase 1 Interventional Results available

A Pilot Study of RNS60 in Amyotrophic Lateral Sclerosis (ALS)

NCT02525471
View directory record Official record
Conditions
ALS
Interventions
RNS60
Drug
Lead sponsor
Sabrina Paganoni, M.D.
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2021 · Synced Oct 18, 2026, 10:16 AM EDT
Completed Phase 4 Interventional Results available

Trial Liposomal Bupivacaine Following Retropubic Suburethral Sling for Stress Urinary Incontinence

NCT02296099
View directory record Official record
Conditions
Urinary Incontinence, Stress
Interventions
liposomal bupivacaine, Placebo
Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 18, 2026, 10:16 AM EDT
Completed Phase 2 Interventional Results available

Study of ARO-ANG3 in Adults With Mixed Dyslipidemia

NCT04832971
View directory record Official record
Conditions
Mixed Dyslipidemia
Interventions
ARO-ANG3, Placebo
Drug
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
13
States / cities
Huntington Park, California • Hialeah, Florida • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 18, 2026, 10:16 AM EDT
Completed Phase 2 Interventional Results available

Modulation of Pharmacologically Induced Alcohol Craving in Recently Detoxified Alcoholics

NCT00605904
View directory record Official record
Conditions
Alcoholism
Interventions
Acamprosate, Yohimbine, mCPP, Saline
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 3, 2012 · Synced Oct 18, 2026, 10:16 AM EDT
Terminated Not applicable Interventional Results available

Subcutaneous Botulinum Toxin for Cutaneous Allodynia - Enriched Responder Trial

NCT00822926
View directory record Official record
Conditions
Pain
Interventions
Botulinum Toxin Type A, Saline
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 100 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 15, 2017 · Synced Oct 18, 2026, 10:16 AM EDT